Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller

European Journal of Surgical Oncology

Volumn 37, Issue 1, 2011, Pages 18-24

  Lai, H W ^a,b   Kuo, S J ^a,c   Chen, L S ^d   Chi, C W ^b   Chen, S T ^a   Chang, T W ^e,f   Chen, D R ^a,d  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Estrogen receptor; HER 2; Progesterone receptor; Triple negative breast cancer; Tumor size

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; YOUNG ADULT;

EID: 78650295428     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.10.003     Document Type: Article

References (30)

1. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
2. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
3. C. Sotiriou, S.Y. Neo, and L.M. McShane Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci U S A 100 2003 10393 10398
4. J.D. Brenton, L.A. Carey, A.A. Ahmed, and C. Caldas Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 2005 7350 7360
5. T.O. Nielsen, F.D. Hsu, and K. Jensen Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
6. E.A. Rakha, J.S. Reis-Filho, and I.O. Ellis Basal-like breast cancer: a critical review J Clin Oncol 26 2008 2568 2581
7. S. Cleator, W. Heller, and R.C. Coombes Triple-negative breast cancer: therapeutic options Lancet Oncol 8 2007 235 244
8. O. Gluz, C. Liedtke, and N. Gottschalk Triple-negative breast cancer-current status and future directions Ann Oncol 20 2009 1913 1927
9. W.J. Yin, J.S. Lu, and G.H. Di Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients Breast Cancer Res Treat 115 2009 325 333
10. L.G. Fulford, J.S. Reis-Filho, and K. Ryder Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival Breast Cancer Res 9 2007 R4
11. C. Liedtke, C. Mazouni, and K.R. Hess Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 2008 1275 1281
12. Y. Lin, W. Yin, and T. Yan Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients BMC Cancer 9 2009 342
13. D. Saslow, C. Boetes, and W. Burke American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography CA Cancer J Clin 57 2007 75 89 (Pubitemid 46535708)
14. W.A. Berg, J.D. Blume, and J.B. Cormack Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer JAMA 299 2008 2151 2163
15. C.H. Lee, D.D. Dershaw, and D. Kopans Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer J Am Coll Radiol 7 2010 18 27
16. A. Goldhirsch, J.N. Ingle, and R.D. Gelber Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
17. NCCN Clinical Practice Guidelines in Oncology: breast cancer 2010 National Comprehensive Cancer Network http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf
18. B. Pestalozzi, and M. Castiglione Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 19 Suppl. 2 2008 ii7 ii10
19. F.L. Greene, D.L. Page, and I.D. Fleming AJCC cancer staging manual 6th ed. 2002 Springer-Verlag New York, NY
20. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
21. Y.H. Park, S.T. Kim, and E.Y. Cho A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119 2010 653 661
22. B. Cady, M.D. Stone, and J.G. Schuler The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening Arch Surg 131 1996 301 308
23. Y.Y. Chen, and S.J. Schnitt Prognostic factors for patients with breast cancers 1cm and smaller Breast Cancer Res Treat 51 1998 209 225
24. A.J. Evans, E.A. Rakha, and S.E. Pinder Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up J Med Screen 14 2007 210 214
25. S.P. Leitner, A.S. Swern, D. Weinberger, L.J. Duncan, and R.V. Hutter Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a, b N0 M0) Cancer 76 1995 2266 2274
26. H. Joensuu, J. Isola, and M. Lundin Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 2003 923 930
27. S. Chia, B. Norris, and C. Speers Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 2008 5697 5704
28. Y.H. Choi, J.H. Ahn, and S.B. Kim Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis Ann Oncol 20 2009 1337 1343
29. A. Goldhirsch, W.C. Wood, and R.D. Gelber Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 2007 1133 1144
30. E. Warner, H. Messersmith, and P. Causer Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer Ann Intern Med 148 2008 671 679